Company: LENZ
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001815776-25-000032
Chunk: 289

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 289
---
,931 16,088 Loss from operations(16,931)(16,088)Other income (expense):Other expense(11)(1,348)Interest income2,323 788 Total other income (expense), net2,312 (560)Net loss$(14,619)$(16,648)Other comprehensive loss:Unrealized loss on marketable securities(73)(7)Comprehensive loss$(14,692)$(16,655)Net loss per share, basic and diluted$(0.53)$(3.53)Weighted-average common shares outstanding, basic and diluted (1)27,526,0994,717,613

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 

(1)See Note 2 for further information on weighted-average common shares outstanding.

2

Table of Contents

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)

(unaudited)

Stockholders' Equity (Deficit)Common StockAdditionalPaid-inCapitalAccumulatedDeficitAccumulatedOtherComprehensiveIncome (Loss)Stockholders' Equity(Deficit)SharesAmountBalance as of December 31, 202427,518,439$1 $348,901 $(145,014)$196 $204,084 Exercise of stock options and common warrants11,630— 44 — — 44 Unrealized loss on marketable securities—— — — (73)(73)Vesting of early exercised stock options5,594— 19 — — 19 Share-based compensation—— 2,555 — — 2,555 Net loss—— — (14,619)— (14,619)Balance as of March 31, 202527,535,663$1 $351,519 $(159,633)$123 $192,010 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

LENZ THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED AND COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)

(in thousands, except share data)

(unaudited)

Convertible Preferred and Common StockStockholders' Equity (Def